NASDAQ:VERA

Vera Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy VERA

*Your capital is at risk

$31.27

+0.0100 (+0.0320%)

At Close: Jun 03, 2026

Vera Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 29.42. In total, the insiders bought 2.13M and sold 163.18K VERA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	29.42
● Buy	2.13M shares
● Sell	163.18K shares
77% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence May 12, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 29.42. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 23, 2026 Sell	Class A Common Stock S-Sale	Young Joseph R SVP, Finance, Chief Acct Offcr	Officer	3 117 Value: $130.9K
Feb 23, 2026 Sell	Class A Common Stock S-Sale	Brenner Robert Chief Medical Officer	Officer	2 151 Value: $90.3K
Feb 04, 2026 Buy	Class A Common Stock A-Award	Young Joseph R SVP, Finance, Chief Acct Offcr	Officer	10 000 Value: $427.4K
Feb 04, 2026 Buy	Stock Option (right to buy) A-Award	Young Joseph R SVP, Finance, Chief Acct Offcr	Officer	20 000 Value: $854.8K
Feb 04, 2026 Buy	Class A Common Stock A-Award	Fordyce Marshall President And CEO	CEO / President	68 800 Value: $2.94M
Feb 04, 2026 Buy	Stock Option (right to buy) A-Award	Fordyce Marshall President And CEO	CEO / President	137 500 Value: $5.88M
Feb 04, 2026 Buy	Stock Option (right to buy) A-Award	Turner William D. Chief Regulatory Officer	Officer	50 000 Value: $2.14M
Feb 04, 2026 Buy	Class A Common Stock A-Award	Turner William D. Chief Regulatory Officer	Officer	25 000 Value: $1.07M
Feb 04, 2026 Buy	Class A Common Stock A-Award	Johnson David Lee Chief Operating Officer	C-Suite Officer	20 000 Value: $854.8K
Feb 04, 2026 Buy	Class A Common Stock A-Award	Grant Sean Chief Financial Officer	C-Suite Officer	25 000 Value: $1.07M
Feb 04, 2026 Buy	Stock Option (right to buy) A-Award	Grant Sean Chief Financial Officer	C-Suite Officer	50 000 Value: $2.14M
Feb 04, 2026 Buy	Class A Common Stock A-Award	Skelton Laurence Matthew Chief Commercial Officer	Officer	20 000 Value: $854.8K
Feb 04, 2026 Buy	Stock Option (right to buy) A-Award	Skelton Laurence Matthew Chief Commercial Officer	Officer	40 000 Value: $1.71M
Feb 04, 2026 Buy	Stock Option (right to buy) A-Award	Johnson David Lee Chief Operating Officer	C-Suite Officer	40 000 Value: $1.71M
Feb 04, 2026 Buy	Class A Common Stock A-Award	Brenner Robert Chief Medical Officer	Officer	25 000 Value: $1.07M
Feb 04, 2026 Buy	Stock Option (right to buy) A-Award	Brenner Robert Chief Medical Officer	Officer	50 000 Value: $2.14M
Jan 20, 2026 Buy	Class A Common Stock	Skelton Laurence Matthew Chief Commercial Officer	Officer	0 Value: $0
Jan 20, 2026 Buy	Class A Common Stock	Skelton Laurence Matthew Chief Commercial Officer	Officer	0 Value: $0
Jan 20, 2026 Buy	Stock Option (right to buy)	Skelton Laurence Matthew Chief Commercial Officer	Officer	60 000 Value: $2.51M
Jan 20, 2026 Buy	Stock Option (right to buy)	Skelton Laurence Matthew Chief Commercial Officer	Officer	31 500 Value: $919.2K
Dec 15, 2025 Sell	Class A Common Stock S-Sale	Turner William D. Chief Regulatory Officer	Officer	10 000 Value: $500.8K
Dec 15, 2025 Buy	Class A Common Stock M-Exempt	Turner William D. Chief Regulatory Officer	Officer	10 000 Value: $155.3K
Dec 15, 2025 Buy	Stock Option (right to buy) M-Exempt	Turner William D. Chief Regulatory Officer	Officer	10 000 Value: $155.3K
Dec 11, 2025 Buy	Class A Common Stock P-Purchase	Enright Patrick G Director	Director	5 882 Value: $250.0K
Dec 08, 2025 Sell	Class A Common Stock S-Sale	Turner William D. Chief Regulatory Officer	Officer	10 000 Value: $453.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT VERA THERAPEUTICS, INC.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of ...

Read Full Profile Here